Progenics Pharmaceuticals Inc (PGNX) SEC Filing 8-K Material Event for the period ending Tuesday, June 16, 2020

Progenics Pharmaceuticals Inc

CIK: 835887 Ticker: PGNX

View differences made from one to another to evaluate Progenics Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Progenics Pharmaceuticals Inc.


Assess how Progenics Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Progenics Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: PGNX
CIK: 835887
Form Type: 8-K Corporate News
Accession Number: 0001193125-20-171462
Submitted to the SEC: Wed Jun 17 2020 5:16:03 PM EST
Accepted by the SEC: Wed Jun 17 2020
Period: Tuesday, June 16, 2020
Industry: Pharmaceutical Preparations
  1. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: